UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 16, 2020
Poseida Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39376 | 47-2846548 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 9390 Towne Centre Drive, Suite 200 San Diego, California |
92121 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (858) 779-3100
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
| Common stock, par value $0.0001 per share | PSTX | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On December 16, 2020, the Board of Directors (the “Board”) of Poseida Therapeutics, Inc. (the “Company”) appointed Luke Corning as a director of the Company. Mr. Corning will serve as a Class II director with an initial term expiring at the Company’s 2022 annual meeting of stockholders, or until his earlier death, resignation, or removal.
The Company entered into a standard form of indemnity agreement with Mr. Corning effective upon his election to the Board. Mr. Corning has elected not to receive the compensation to which he would otherwise be entitled in accordance with the Company’s Non-Employee Director Compensation Policy.
Also on December 16, 2020, Sean Murphy, a director of the Company, informed the Board that he does not intend to stand for reelection at the Company’s 2021 annual meeting of stockholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Poseida Therapeutics, Inc. | ||||||
| Date: December 17, 2020 | By: | /s/ Harry J. Leonhardt | ||||
| Harry J. Leonhardt | ||||||
| General Counsel and Chief Compliance Officer | ||||||